|
7:30am Pre-Conference Tutorial Registration and Morning Coffee
8:00 Effective Portfolio Management - Aligning Fungible & Non-Fungible Resources to Meet Portfolio Requirements
• Project Management - primary roles and responsibilities
• Project & Program resource demand - estimating $ & FTEs
• Risk Management - quantifying uncontrollable and controllable risks
• Portfolio Management - finding the optimal resource allocation solution
• Functional Capacity Management - ensuring continual and necessary resource
utilization
• Organizational success - linking STRAT Plan, Business Plan, and Portfolio Plan
9:30 Morning Coffee Break
10:00 Demonstration of a Portfolio System
11:00 Facilitated Discussion: Best Practices in Project and Portfolio
Management
11:30 Close of Tutorial
Facilitators: Richard M. Bayney, PhD, MSc, MBA, Vice President, Portfolio Planning, Pharmaceutical Research & Development, Johnson & Johnson and Donald Kane, Senior Consultant, CA
About
the Facilitator
Rick Bayney joined Johnson & Johnson's Pharmaceutical Research & Development
(PRD) in 2002 as Vice President, Decision Analysis & Portfolio Management. His primary challenge was to create a department responsible for the implementation of Decision Analysis & Portfolio Management. He is currently responsible for (a) Decision Analysis support of Compound Development Teams for stage-gate decision-making in early and late Clinical Development, (b) risk assessment and portfolio impact analyses of Licensing opportunities, (c) analytical and strategic project and portfolio support to Therapeutic Area Centers of Excellence and (d) portfolio management support for
PRD, from Drug Discovery to late Clinical Development. Prior to his arrival at J&J
PRD, he was Executive Director of Decision Analysis & Portfolio Management at Bristol-Myers Squibb responsible for project and portfolio support to pre-clinical and clinical development. At Bristol-Myers Squibb, he was responsible for creating a Decision Analysis & Portfolio Management department across R&D. Before joining Bristol-Myers Squibb, he was the Head of Strategic Planning for the Biotechnology division of Bayer Corporation where he was responsible for Decision Analysis and Portfolio Management support for the Biotechnology portfolio.
Rick spent 10 years in Molecular Biology research at Merck & Company and Bayer Corporation/A.G. during which time he authored/co-authored more than 20 reviewed papers on hepatic drug detoxification and Alzheimer's Disease. He also spent 2 years on a foreign assignment as an international Project Manager in the area of cardiovascular diseases. Rick is a frequent speaker in the area of 'Risk Analysis, Asset Evaluation & Portfolio Management in Drug Development' and is also an Advisory Board Member to Cambridge Healthtech Institute. He holds MSc and PhD degrees from London University and an MBA from Columbia University.
*Separate Registration Required |
